| Market Cap | 347.31M | P/E | 132.50 | EPS this Y | - | Ern Qtrly Grth | 48.70% |
| Income | 5.5M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -2.00% |
| Sales | 3.51M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -6.00% |
| Dividend | 10.00% | Price/Book | 0.82 | EPS next 5Y | - | 52W High Chg | -19.00% |
| Recommedations | - | Quick Ratio | 0.00 | Shares Outstanding | 27.35M | 52W Low Chg | 1.00% |
| Insider Own | 0.01% | ROA | -0.32% | Shares Float | - | Beta | 0.71 |
| Inst Own | 37.22% | ROE | 1.28% | Shares Shorted/Prior | 172.76K/221.52K | Price | 13.25 |
| Gross Margin | 100.00% | Profit Margin | 156.45% | Avg. Volume | 86,883 | Target Price | - |
| Oper. Margin | -31.63% | Earnings Date | Dec 9 | Volume | 128,629 | Change | -0.60% |
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Maher Bill | Director Director | Dec 28 | Buy | 13.57 | 1,000 | 13,570 | 1,000 | 01/02/24 |
| OMSTEAD DANIEL R | President President | Sep 25 | Buy | 12.3926 | 10,096 | 125,116 | 197,518 | 09/25/23 |
| OMSTEAD DANIEL R | President President | Sep 20 | Buy | 12.6838 | 12,000 | 152,206 | 187,422 | 09/20/23 |
| Goetz Kathleen | Director Director | Mar 23 | Buy | 16.2700 | 92 | 1,502 | 685 | 03/24/22 |
| Goetz Kathleen | Director Director | Jan 26 | Buy | 17.5441 | 593 | 10,404 | 593 | 01/27/22 |